Diabetes and risk of Parkinson's disease

Diabetes Care

Volumn 34, Issue 4, 2011, Pages 910-915

  Xu, Qun ^a   Park, Yikyung ^b   Huang, Xuemei ^c   Hollenbeck, Albert ^d   Blair, Aaron ^b   Schatzkin, Arthur ^b   Chen, Honglei ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d AARP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; COFFEE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GENDER; HEALTH STATUS; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PARKINSON DISEASE; PROSPECTIVE STUDY; RISK ASSESSMENT; SELF REPORT; SMOKING; STROKE; UNITED STATES;

AGED; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PARKINSON DISEASE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 79956218430     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1922     Document Type: Article

References (25)

1. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263-1268
2. American Diabetes Association American Academy of Neurology. Consensus statement: report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988;11:592-597
3. Peila R, Rodriguez BL, Launer LJ; Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002;51:1256-1262
4. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004;61:661-666 (Pubitemid 38637681)
5. Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Diabetes in patients with idiopathic Parkinson's disease. Diabetes Care 2008;31:1808-1812
6. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord 2006;12:185-189
7. Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 2006;37:1184-1188 (Pubitemid 43731859)
8. D'Amelio M, Ragonese P, Callari G, et al. Diabetes preceding Parkinson's disease onset. A case-control study. Parkinsonism Relat Disord 2009;15:660-664
9. Driver JA, Smith A, Buring JE, Gaziano JM, Kurth T, Logroscino G. Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2008;31:2003-2005
10. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007;30:842-847 (Pubitemid 46562366)
11. Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007;69:1688-1695 (Pubitemid 350287125)
12. Schatzkin A, Subar AF, Thompson FE, et al. Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol 2001;154:1119-1125 (Pubitemid 33140635)
13. Chen H, Huang X, Guo X, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010;74:878-884
14. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008
15. Unger JW, Livingston JN, Moss AM. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol 1991;36:343-362
16. Scranton R, Cincotta A. Bromocriptine - unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother 2010;11:269-279
17. Schintu N, Frau L, Ibba M, et al. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci 2009;29:954-963
18. Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev 2007;65:S152-S156
19. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 2008;167:90-95
20. Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci 1993;69:125-130
21. Friederich M, Hansell P, Palm F. Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr Diabetes Rev 2009;5:120-144
22. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008;4:600-609
23. Miyake Y, Tanaka K, Fukushima W, et al.; Fukuoka Kinki Parkinson's Disease Study Group. Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci 2010;293:82-86
24. Nataraj A, Rajput AH. Parkinson's disease, stroke, and related epidemiology. Mov Disord 2005;20:1476-1480 (Pubitemid 43072657)
25. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between selfreport questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004;57:1096-1103 (Pubitemid 39446649)